In the News
Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
Gateway for Cancer Research accelerates practice-changing clinical trials to cancer research by harnessing the unrelenting passion of the research community and empowering patients to triumph over their disease. All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.
Balstilimab Plus Botensilimab Shows Better Response in MSS mCRC
Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver metastases.
Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC
Neoadjuvant botensilimab and balstilimab showed high MPR rates in MSS and MSI-H CRC, with no recurrences reported.
Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC
The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.
Combination Slows Metastatic CRC Progression Better Than Single Immunotherapy
An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study.
Botensilimab Plus Balstilimab Elicits Encouraging Responses in MSS mCRC Without Liver Mets
Balstilimab and botensilimab combination therapy showed superior efficacy in MSS mCRC patients without liver metastases compared to botensilimab monotherapy.